The Effectiveness of Varicella Vaccination in Children in Germany
NCT ID: NCT00679796
Last Updated: 2012-10-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1012 participants
OBSERVATIONAL
2008-02-29
2010-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Subjects with PCR confirmed varicella
Varicella (chickenpox) lesion sampling
Group B
Age- and practice-matched control subjects
Varicella (chickenpox) lesion sampling
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Varicella (chickenpox) lesion sampling
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Residence in Germany
* At least one previous well-child visit to the practice
* Written informed consent obtained from parents/guardians of the subject as per local requirements.
* Specific inclusion criterion for cases:
* Suspected primary varicella disease (i.e. chickenpox) at the time of study entry
Exclusion Criteria
* History of hypersensitivity to any of the components of the vaccines
* Congenital or acquired immunodeficiency
* Treatment with immunosuppressive therapy
* HIV-infected patients, when CD4 \< 25% of total lymphocytes
* Previous history of chickenpox by physician record or parental report.
* Lack of documented vaccination history (written or computerised practice records or child's vaccination card/booklet).
1 Year
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ludwig-Maximilians - University of Munich
OTHER
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Baldham, Bavaria, Germany
GSK Investigational Site
Deisenhofen, Bavaria, Germany
GSK Investigational Site
Freising, Bavaria, Germany
GSK Investigational Site
Fürstenfeldbruck, Bavaria, Germany
GSK Investigational Site
Gilching, Bavaria, Germany
GSK Investigational Site
Grafing, Bavaria, Germany
GSK Investigational Site
Grafrath, Bavaria, Germany
GSK Investigational Site
Kirchheim, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Olching, Bavaria, Germany
GSK Investigational Site
Taufkirchen, Bavaria, Germany
GSK Investigational Site
Weilheim, Bavaria, Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Liese J et al. Effectiveness of one dose of varicella vaccine after introduction of routine varicella vaccination in Germany. Abstract presented at the 20th Congress of German Society for pediatric infectious diseases (GSPID). e.V.Mannheim, Germany, 19-21 April 2012.
Liese J et al. Pediatric practice-based case-control study to evaluate the effectiveness of vaccination against laboratory-confirmed varicella in young children in Germany. Abstract presented at the 30th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID) meeting, Thessaloniki, Greece 8-12 May 2012.
Liese JG, Cohen C, Rack A, Pirzer K, Eber S, Blum M, Greenberg M, Streng A. The effectiveness of varicella vaccination in children in Germany: a case-control study. Pediatr Infect Dis J. 2013 Sep;32(9):998-1004. doi: 10.1097/INF.0b013e31829ae263.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
109737
Identifier Type: -
Identifier Source: org_study_id